BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Eli Lilly and Company
Pfizer
RemeGen Co., Ltd.
Astellas Pharma Inc
Shanghai Chest Hospital
Pfizer
M.D. Anderson Cancer Center
Amgen
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
AstraZeneca
University of Rochester
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
Abramson Cancer Center at Penn Medicine
AstraZeneca
National Cancer Institute (NCI)
Tesaro, Inc.
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
BeiGene
University Health Network, Toronto
Merck Sharp & Dohme LLC
Peking University Cancer Hospital & Institute
Ohio State University Comprehensive Cancer Center
Shanghai Junshi Bioscience Co., Ltd.
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
Boehringer Ingelheim
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
GlaxoSmithKline
Arcus Biosciences, Inc.
Genentech, Inc.
The Netherlands Cancer Institute
Jiangsu Hansoh Pharmaceutical Co., Ltd.
University of Chicago
MedImmune LLC
Sichuan University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Canadian Cancer Trials Group
Sichuan University
Cantargia AB
Blueprint Medicines Corporation
Saint John's Cancer Institute